(Q40804482)

23 September 2017

1 reference

title

Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin (English)

1 reference

23 September 2017

McNamee P

1

1 reference

23 September 2017

van Doorslaer E

series ordinal

2

1 reference

23 September 2017

Segaar R

series ordinal

3

1 reference

23 September 2017

publication date

1 January 1993

1 reference

International Journal of Technology Assessment in Health Care

23 September 2017

published in

1 reference

23 September 2017

volume

9

1 reference

23 September 2017

issue

4

1 reference

23 September 2017

page(s)

490-504

1 reference

Erythropoietin--trials then tribulation

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Recombinant human erythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Improvement of Kidney-Graft Survival with Increased Numbers of Blood Transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Measuring the wellbeing of family caregivers using the time trade-off technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Implications of recombinant erythropoietin therapy for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Cost-effectiveness of weekly and fortnightly subcutaneous erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Subcutaneous erythropoietin

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Erythropoietin: Off again, on again

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Canadian Hemodialysis Morbidity Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Recombinant erythropoietin therapy in cancer patients

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Application of recombinant human erythropoietin in oncology

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

The quality of life of patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

https://api.crossref.org/works/10.1017%2FS0266462300005419

1 reference

7 January 2021

Recombinant human erythropoietin: factors to consider in cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300005419

7 January 2021

10.1017/S0266462300005419

Identifiers

DOI

1 reference

23 September 2017

1 reference